Redeye comments on Imint's Q1 report, which showed all-time highs in net revenues and stable profita...
Biovica’s CLIA certified San Diego lab, together with the summer of 2022 FDA 510 (k) approval is the...
Redeye provides its comments on CLS’ Q1’22 report. With ongoing discussions with potential new comme...
Rapportkommentar Calliditas presenterade under onsdagen sin Q1-rapport – det första kvartalet med fö...
Fortsatt starkt affärsläge... Lagercrantz rapporterade en organisk tillväxt på 20% där förvärv bidro...
Redeye notes that the SEK 30m short-term financing should carry operations until the latter part of ...
Redeye initiates coverage of TH1NG, a Swedish Internet of Things (IoT) platform provider with potent...
Redeye has a positive view of Active Biotech’s obtaining orphan drug status.
Redeye makes minor estimate changes and has a positive take on the deepened partnership with Newsec,...
Soltech Energy redovisade stark tillväxt under årets inledande kvartal.
Redeye resumes coverage of Azelio following its introduction of new operational targets for the comi...
Redeye returns following the conference call and chat with management with more flesh on the bones r...
Our analyst summarizes the investment case: “Fluicell offers innovative R&D instruments for single-c...
Redeye comments on Embracers Q4 21/22 report. We view the report as encouraging.
Redeye was surprised by the magnitude of price inflation displayed in the Q1 numbers.
I dag offentliggjorde Risk Intelligence sin delårsrapport för det första kvartalet 2022.
Redeye lowers Orexo’s valuation to SEK 42 per share as it becomes clear that there is persistent wea...
NOSIUM publicerade idag den 18 maj bolagets delårsrapport för första kvartalet 2022.
Sales estimates down for ’22e, up in ’23e-’24e (~3.
Fantasma Games AB (”Fantasma” eller ”Bolaget”) utvecklar och producerar spel till den globala casino...
